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and meta–analysis
Background The burden of chronic obstructive pulmonary disease 
(COPD) across many world regions is high. We aim to estimate COPD 
prevalence and number of disease cases for the years 1990 and 2010 
across world regions based on the best available evidence in publicly 
accessible scientific databases.
Methods We conducted a systematic search of Medline, EMBASE and 
Global Health for original, population–based studies providing spirom-
etry–based prevalence rates of COPD across the world from January 
1990 to December 2014. Random effects meta–analysis was conducted 
on extracted crude prevalence rates of COPD, with overall summaries 
of the meta–estimates (and confidence intervals) reported separately for 
World Health Organization (WHO) regions, the World Bank's income 
categories and settings (urban and rural). We developed a meta–regres-
sion epidemiological model that we used to estimate the prevalence of 
COPD in people aged 30 years or more.
Findings Our search returned 37 472 publications. A total of 123 stud-
ies based on a spirometry–defined prevalence were retained for the re-
view. From the meta–regression epidemiological model, we estimated 
about 227.3 million COPD cases in the year 1990 among people aged 
30 years or more, corresponding to a global prevalence of 10.7% (95% 
confidence interval (CI) 7.3%–14.0%) in this age group. The number 
of COPD cases increased to 384 million in 2010, with a global preva-
lence of 11.7% (8.4%–15.0%). This increase of 68.9% was mainly driv-
en by global demographic changes. Across WHO regions, the highest 
prevalence was estimated in the Americas (13.3% in 1990 and 15.2% 
in 2010), and the lowest in South East Asia (7.9% in 1990 and 9.7% in 
2010). The percentage increase in COPD cases between 1990 and 2010 
was the highest in the Eastern Mediterranean region (118.7%), followed 
by the African region (102.1%), while the European region recorded the 
lowest increase (22.5%). In 1990, we estimated about 120.9 million 
COPD cases among urban dwellers (prevalence of 13.2%) and 106.3 
million cases among rural dwellers (prevalence of 8.8%). In 2010, there 
were more than 230 million COPD cases among urban dwellers (prev-
alence of 13.6%) and 153.7 million among rural dwellers (prevalence 
of 9.7%). The overall prevalence in men aged 30 years or more was 
14.3% (95% CI 13.3%–15.3%) compared to 7.6% (95% CI 7.0%–
8.2%) in women.
Conclusions Our findings suggest a high and growing prevalence of 
COPD, both globally and regionally. There is a paucity of studies in Af-
rica, South East Asia and the Eastern Mediterranean region. There is a 
need for governments, policy makers and international organizations to 
consider strengthening collaborations to address COPD globally.
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In a follow–up to the 2011 United Nations (UN) high lev-
el political declaration on non-communicable diseases 
(NCDs) [1], the World Health Assembly, in 2012, endorsed 
a new health goal (the “25 by 25 goal”), which focuses on 
reduction of premature deaths from COPD and other 
NCDs by 25% by the year 2025 [2]. Despite this initiative, 
experts have reported that COPD remains a growing [3], 
but neglected global epidemic [4]. The World Health Or-
ganization (WHO) estimated that there were about 62 mil-
lion people with moderate to severe COPD in 2002, with 
the total number of COPD cases predicted to increase to 
about 200 million in 2010 [5,6]. According to the 2010 
Global Burden of Disease (GBD) study, COPD was respon-
sible for about 5% of global disability–adjusted life years 
– DALYs (76.7 million) – and 5% of total deaths (2.9 mil-
lion) [7,8]. COPD is currently rated the fourth most com-
mon specific cause of death globally and predicted to be 
the third by 2030, in the absence of interventions that ad-
dress the risks – especially tobacco smoking, exposures to 
combustion products of biomass fuels and environmental 
pollution [9,10].
The burden of COPD has been reported to be high in some 
high–income countries (HIC), particularly due to high 
prevalence of smoking in these settings [11]. For example, 
between years 2000 and 2010, about 4%–10% of adults 
were diagnosed with non–reversible and progressive air-
way obstruction (a basic feature of COPD) in population–
based surveys across many European countries, with smok-
ing indicated as a major risk [12]. The WHO has estimated 
that in many HIC up to 73% of COPD deaths are related 
to tobacco smoking [6]. The European Union (EU) report-
ed that the direct cost from COPD was over 38.6 billion 
Euros in 2005, representing about 3% of total health care 
expenditure [13,14]. In the United States (US), over 2.7 
million adults were estimated to have COPD in 2011, with 
about 135 000 deaths reported [15]. In 2010, the US gov-
ernment spent nearly US$ 49.9 billion on COPD, includ-
ing 29.5 billion spent on direct health care, 8.0 billion on 
indirect morbidity and 12.4 billion on indirect mortality 
costs, respectively [15].
Meanwhile, it has been estimated that despite a high prev-
alence of COPD in some HIC, 90% of COPD deaths still 
occur in LMIC [4] and 40% of these deaths are attributable 
to smoking [6]. The burden in LMIC has been compara-
tively high owing to relatively low COPD awareness, chal-
lenges with COPD diagnosis and increased exposures to 
additional risk factors, especially combustion products of 
biomass fuels [16]. Salvi and colleagues reported that about 
3 billion people globally are exposed to smoke from bio-
mass fuel, compared to 1 billion people who smoke tobac-
co globally [17]. In many developing countries COPD is 
neglected by governments, physicians, experts and the 
pharmaceutical industry, although it's been identified as an 
important public health problem [4].
In the last two decades, the Burden of Obstructive Lung 
Disease (BOLD) initiative has been collecting country–spe-
cific data on the prevalence, risk factors and socioeconom-
ic burden of COPD, using standardized and tested methods 
for conducting COPD surveys in the general population 
[18]. This is expected to provide governments of many na-
tions with country–specific evidence on which to develop 
policy on COPD prevention and management [18]. As not-
ed above, this initiative is yet to take a full effect in many 
LMIC [19]. In addition, spirometry (the gold standard for 
COPD diagnosis) is not widely available in many LMIC 
[16]. Even when it is there, professionals in LMIC are often 
not being trained properly on how to use spirometers or 
interpret spirometry results. There is concern that COPD 
burden has been underestimated, owing to over–reliance 
on doctor’s diagnosis, with many diagnoses not being based 
on spirometry and international diagnostic guidelines [20]. 
The lack of routine COPD data collation and effective 
health information management system in many LMIC also 
implies that these settings could have been grossly under–
represented in global burden of COPD estimates [11].
Some global and regional estimates of COPD burden have 
been published [1,21–23]. However, despite the fact that 
COPD is now prevalent in both HIC and LMIC, experts 
have raised concerns that reliable estimates of COPD prev-
alence are still few in many parts of the world. Moreover, 
many of the estimates are based on varying definitions and 
diagnostic criteria of COPD [9]. Also, some of the current 
estimates were reported before the BOLD surveys in sev-
eral countries, thereby failing to account for the additional 
spirometry–based epidemiological data from the BOLD 
surveys. There is a need for a revised and updated estimate 
of COPD prevalence across world regions. We conducted 
a systematic review of COPD prevalence based on spirom-
etry data across world regions. Our aim was to provide 
global and regional prevalence rates of COPD that could 
facilitate adequate policy response in these regions.
METHODS
Search strategy and selection criteria
After identifying relevant Medical Subject Headings 
(MeSH), we conducted a systematic search of Medline, EM-
BASE and Global Health for studies estimating the preva-
lence of COPD globally from January 1990 to December 
2014. We also searched Google Scholar for unpublished 
studies. Reference lists of retained publications were further 
hand-searched for studies omitted in our initial searches 
(see search terms in Tables s1–3 in Online Supplemen-
tary Document).
December 2015  •  Vol. 5 No. 2 •  020415	 2	 www.jogh.org •  doi: 10.7189/jogh.05.020415
V
IE
W
PO
IN
TS
PA
PE
RS
Global and regional estimates of COPD prevalence
We included original population–based (cohort or cross–
sectional) studies conducted worldwide. The retained stud-
ies provided estimates of the prevalence and number of 
cases of COPD and/or relevant population–based informa-
tion from which COPD prevalence could be estimated. We 
excluded studies that had unclear study designs and meth-
odologies, conducted before 1990, on non–human sub-
jects, and that were reviews, viewpoints or editorials. No 
language restrictions were applied.
Case definitions
Based on an understanding of the diagnosis of COPD as 
reported by respiratory physicians, we included only stud-
ies that were based on spirometry, as these have been 
shown to be consistent with the diagnosis of COPD world-
wide [24,25]. However, it is important to note that experts 
may still not fully agree on the spirometry–based definition 
that best defines COPD [26]. In 2001, the Global initiative 
on Obstructive Lung Disease (GOLD) recommended using 
the ratio of forced expiratory volume in one second (FEV
1
) 
to forced vital capacity (FVC) that is less than 70% in the 
diagnosis of COPD (FEV
1
/FVC<70%) [25,27]. This diag-
nostic criterion was also endorsed by the American Tho-
racic Society (ATS) and the European Respiratory Society 
(ERS) in 2004 [28]. It has been acknowledged that this cri-
terion is simple and independent of reference equations 
[26]. However, the use of a fixed FEV
1
/FVC ratio has been 
debated from a number of perspectives [29–32], which we 
summarized in the discussion (see later). For the current 
study, we selected studies that used case definitions for 
COPD as shown in detail in Table 1.
Data extraction, synthesis of results and 
analysis
All extracted data were stored in Microsoft Excel file for-
mat. A parallel search and extraction was conducted by 
three independent reviewers (SC, CL and CB). Any dis-
agreement between the three reviewers over article inclu-
sion, exclusion and/or data extraction for the current study 
was resolved through re-review of their work and agree-
ment between their two supervisors (DA and IR). We did 
not calculate Kappa statistics for the agreement between all 
reviewers because it was not amenable to straightforward 
computation and interpretation in this two-stage extraction 
process, which was based on a mix of independent review 
and collaborative re-review. Also, we did not make any at-
tempts to contact the authors of studies that were rejected 
based on unclear reporting. Data were abstracted system-
atically on sample size, mean age, number of COPD cases, 
and the respective age– and sex– specific prevalence rates. 
These were classified into WHO regions, the World Bank's 
income categories, and study setting (urban, rural or 
mixed). For studies conducted on the same study site, pop-
ulation or cohort, the first chronologically published study 
was selected, and all additional data from other studies 
were included in the selected paper. All extracted informa-
tion from the retained studies is available in Table s4 in 
Online Supplementary Document.
A random effect meta–analysis (DerSimonian and Laird 
method) was conducted on extracted crude prevalence 
rates of COPD [33]. Overall summaries of the meta–esti-
mates (and confidence intervals) were reported separately 
for the WHO regions, the World Bank's income categories, 
and study settings, all expressed as percentages.
We developed a meta–regression epidemiological model 
and applied this on crude prevalence rates of COPD. In this 
model, mean ages corresponding to each prevalence rate 
were plotted on the x–axis (independent variable) and 
crude prevalence rates were plotted on the y–axis (depen-
dent variable). We accounted for variation in sample sizes 
from each data point and controlled for year of publication 
to generate estimates of COPD prevalence for the years 
1990 and 2000, respectively. The best fit was then used in 
our model and the equation generated from the fitted line 
was applied to the respective midpoints of the United Na-
tions (UN) 5–year age–group population estimates for the 
years 1990 and 2010, respectively (United Nations, 2013). 
This enabled us to determine the prevalence of COPD glob-
Table 1. Basic characteristics of the studies retained for the 
analyses (a total of 140 study sites from 123 studies)
CharaCteristiCs study sites
WHO regions:
AFRO 6
AMRO 15
EMRO 7
EURO 64
SEARO 6
WPRO 42
Income category:
High 87
Low and middle 53
Settings:
Mixed* 52
Urban 63
Rural 25
Study period:
1990–1999 24
2000–2009 94
2010–present 22
COPD case definitions:
FEV
1
/FVC<70% 130
FEV
1
/FVC<LLN 8
FEV
1
/FVC<75% 1
FEV
1
/FVC≤65% 1
COPD – chronic obstructive pulmonary disease, FEV – forced expiratory 
volume, FVC – forced vital capacity, LLN – lower limit of normal
*Studies presenting a joint COPD estimate for urban and rural settings.
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ally and in the WHO regions. A detailed description of our 
model has been explained in our previous study where we 
estimated the burden of COPD in Africa [34]. All analyses 
were conducted in Stata 13.1 (Stata Corp LP, College Sta-
tion, Texas, USA).
RESULTS
Systematic review
Our search returned 37 472 publications: 10 828 in Med-
line, 24 265 in EMBASE and 2379 in Global Health. A fur-
ther three studies were included from other sources (Google 
Scholar and hand–searching reference list of relevant pub-
lications). 23 457 studies remained after removing dupli-
cates. After screening titles for relevance (studies estimating 
the burden of COPD) 21 762 studies were excluded. We 
therefore assessed 1694 full–text papers. After applying the 
quality criteria, 1566 studies were excluded. This is be-
cause 934 articles did not provide prevalence data on 
COPD, population figures or relevant estimates from which 
prevalence can be calculated; further 325 articles did not 
specify study designs; and 307 studies were not based on 
spirometry and/or clarify COPD case definitions. A total of 
128 studies were retained for the review, with 123 provid-
ing quantitative data for a total of 140 study settings (see 
Figure 1 for the PRISMA flow diagram of study selection).
Study characteristics
The retained studies [23,26,35–155] were conducted 
across 140 locations spread across the six regions of the 
WHO (see Table s4 in Online Supplementary Docu-
ment). European (EURO) and Western Pacific (WPRO) 
regions had the highest number of studies with 64 and 42 
study sites, respectively. This was followed by the Ameri-
can region (AMRO) with 15 study sites. Eastern Mediter-
ranean region (EMRO) had seven study sites, while the Af-
rican region (AFRO) and South East Asia region (SEARO) 
each had six study sites (Table 1). Five studies were con-
ducted in multiple sites. They included the BOLD study 
[40], European Community of Respiratory Health Survey 
(ECRHS) [113], the PLATINO study in Latin America [23] 
and two other studies in Europe [61,89].
A total of 52 countries were represented, with China con-
tributing the largest number of studies (22 in total). The 
mean age across studies was 54.1 years, ranging from 32 
to 74 years. The total population from all studies was 
877 566. The COPD survey guidelines employed across 
selected studies included GOLD, ATS, ATS/ERS and the 
British Thoracic Society (BTS) (see Table s4 in Online Sup-
plementary Document). However, COPD diagnosis was 
based on the diagnostic criterion of FEV
1
/FVC<70% in 
92.2% of all retained studies (see Table 1 and Table s4 in 
Online Supplementary Document for detailed explana-
tion of characteristics of selected studies).
 
 
 
128 studies included in 
qualitative synthesis  
 
123 studies included in 
quantitative synthesis (meta-
analysis) 
37 472 records identified through database 
searching (Medline 10 828, EMBASE 24265 & 
Global Health 2379) 
3 additional records identified through 
other sources  
 
23 457 records after duplicates removed  
23 457 records screened  
 
21 762 records excluded  
1694 full-text articles 
assessed for eligibility  
 
1566 full-text articles excluded 
934 articles did not provide 
prevalence of COPD, population 
figures or relevant estimates from 
which prevalence can be calculated  
325 articles did not specify study 
designs  
307 studies were not based on 
spirometry and/or clarify COPD 
case definitions Figure 1. PRISMA 
flowchart of study 
selection.
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Meta–estimates from crude COPD 
prevalence rates
Forest plots were used to give a visual assessment of the 
pooled crude prevalence along with 95% confidence inter-
vals of COPD by WHO regions, by study settings, and by 
the World Bank income category (Figures 2-4). We used 
the I2-statistic to evaluate heterogeneity in COPD preva-
lence between the retained studies. From the random ef-
fects meta–analysis, a prevalence of 11.4% (CI: 10.8%–
12.0%) was estimated globally in people aged ≥30 years 
(Figure 2). The overall prevalence was higher among men 
(14.3%; CI: 13.3%–15.3%) than women (7.6%; CI: 7.0%–
8.2%) (Table 2).
Among the WHO regions, AMRO region had the highest 
prevalence (14.1%; CI: 11.4%–16.7%), followed by EMRO 
(13.2%; CI: 8.8%–17.7%) and EURO (12.0%; CI: 10.7%–
13.2%). AFRO had an estimated prevalence of 10.6% (CI: 
6.1%–15.1%) and WPRO of 10.0% (CI: 9.0%–11.0%). 
SEARO had the lowest prevalence of 7.8% (CI: 5.3%–
10.4%) (Figure 2 and Table 2).
Across most settings, urban dwellers had higher COPD 
prevalence rates (13.2%; CI: 11.8%–14.7%) than rural 
populations (10.2%; 8.2%–12.2%) (Figure 3 and Table 
2). An analysis according to the World Bank's income cat-
egories revealed that the prevalence was higher in high–in-
come countries (HIC): 12.0% (CI: 11.0%–13.0%), com-
pared to 10.6% (CI: 9.5%–11.6%) in LMIC (Figure 4 and 
Table 2).
Modelled estimates of COPD prevalence 
and number of cases
The initial meta–regression analysis showed a significant 
effect of mean age and the year of study on estimated 
COPD prevalence rates. We therefore controlled for these 
effects in the model (Figure 5 and Table 3) [34]. From the 
model based on meta–regression we estimated about 227.3 
million COPD cases in the year 1990 among people aged 
Table 2. Summary of pooled crude COPD prevalence from 
selected studies (prevalence expressed in percentages for the 
population aged 30 years or older)
Both sexes (95% Ci) Men (95% Ci) WoMen (95% Ci)
World 11.4 (10.8–12.0) 14.3 (13.3–15.3) 7.6 (7.0–8.2)
WHO region:
AFRO 10.6 (6.1–15.1) 15.1 (8.8–21.3) 8.0 (4.1–11.9)
AMRO 14.1 (11.4–16.7) 17.6 (14.6–20.6) 11.8 (9.7–13.9)
EMRO 13.2 (8.8–17.7) 15.3 (5.9–24.7) 6.0 (2.5–9.5)
EURO 12.0 (10.7–13.2) 13.7 (12.0–15.3) 7.6 (6.8–8.5)
SEARO 7.8 (5.3–10.4) 9.3 (4.7–13.9) 3.6 (2.4–4.9)
WPRO 10.0 (9.0–11.0) 14.4 (12.5–16.3) 6.4 (5.3–7.5)
Study setting:
Mixed* 9.7 (8.9–10.5) 13.2 (11.8–14.6) 5.7 (5.3–6.2)
Urban 13.2 (11.8–14.7) 15.7 (13.7–17.7) 9.4 (8.3–10.6)
Rural 10.2 (8.2–12.2) 13.1 (8.5–17.7) 6.3 (4.4–8.2)
Income category:
High 12.0 (11.0–13.0) 14.3 (13.0–15.6) 8.1 (7.3–8.8)
Low and middle 10.6 (9.5–11.6) 14.5 (12.3–16.7) 6.5 (5.8–7.2)
COPD – chronic obstructive pulmonary disease, CI – confidence interval
*Studies presenting a joint COPD estimate for urban and rural settings.
Figure 2. Overall pooled crude prevalence of COPD by WHO regions.
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30 years or more, corresponding to the global prevalence 
of 10.7% (7.3%–14.0%) in this age group. However, the 
number increased to 384 million COPD cases in 2010, cor-
responding to the global prevalence of 11.7% (8.4%–
15.0%). This is an increase of 68.9% and it is driven main-
ly by the global demographic changes over the 20–year 
period (Table 4).
Based on the UN percentage of people living in urban areas 
in 1990 (43.0%) and 2010 (51.6%) [156], we estimated 
the global population in these regions in those two years. 
Our model revealed higher prevalence and number of 
COPD cases among urban dwellers. In 1990, we estimated 
about 120.9 million COPD cases among people aged 30 
years or more, accounting for a prevalence of 13.2% 
(10.0%–16.4%). At the same time, rural dwellers had 
106.3 million cases, accounting for a prevalence of 8.8% 
(6.5%–11.1%). By the year 2010, the number of COPD 
cases among urban dwellers rose to more than 230 million, 
accounting for a prevalence of 13.6% (11.2%–16.9%), and 
about 153.7 million cases among rural dwellers, account-
ing for a prevalence of 9.7% (7.6%–11.8%). The percent-
age of increase in COPD cases between 1990 and 2010 was 
higher among urban dwellers than among rural residents 
(90.5% vs 44.6%, respectively) (Table 5).
DISCUSSION
This study is among the first systematic attempts to estimate 
the prevalence of COPD across the world regions using spi-
rometry–based data. The estimates presented here are based 
on the age range starting from 30 years, while many of the 
previous reviews were based on people aged 40 years or old-
er. An appreciable prevalence of COPD has been reported in 
younger population groups, adding to uncertainties over the 
current epidemiological situation globally.
In the current study, we estimated a global prevalence of 
10.7% (7.3%–14.0%) in 1990 and 11.7% (8.4%–15.0%) in 
2010, corresponding to 227 and 384 million of affected cas-
es in 1990 and 2010, respectively. This estimate is an order 
of magnitude higher than the one presented in the 2001 
World Health Report, estimating a world–wide prevalence 
of COPD of 10.1 per 1000 population (12.1 per 1000 men 
and 8.1 per 1000 women) [157]. A 2006 global review con-
ducted by Halbert and colleagues reported a pooled preva-
lence of 9.2% (7.2–11.0), based on 26 spirometry–based 
estimates – a figure much closer to our estimates [21]. In the 
2005 BOLD study, conducted in 12 sites globally and based 
on post–bronchodilator FEV
1
/FVC<70%, the overall preva-
lence of Stage II or higher COPD was 10.1% (men 11.8% 
and women 8.5%) [40], which is again much closer to our 
results. Given that the estimates presented in the 2001 World 
Health Report were based on doctor’s diagnosis and includ-
ed all ages, this may explain the departure from spirometry-
based estimates. All spirometry–based estimates to date seem 
to be comparable and may be indicative of the usefulness of 
spirometry as a gold standard for COPD diagnosis in popu-
lation–based studies.
The highest COPD prevalence estimated in this study was 
observed in the American region, with an estimated preva-
Figure 3. Overall pooled crude prevalence of COPD by study settings.
Table 3. Summary of meta–regression analysis
PrevalenCe CoeffiCient se t P > t 95% Ci 
loWer
95% Ci 
uPPer
Age 0.1662 0.0633 2.63 0.01 0.0410 0.2913
Year 0.0447 0.0923 0.48 0.629 –0.1377 0.2272
Constant –87.1297 184.5720 –0.47 0.638 –452.1321 277.8727
CI – confidence interval
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lence of 13.3% and 15.2% in 1990 and 2010, respectively. 
Moreover, we estimated that 113 million COPD cases 
should be expected in Western Pacific region in 2010, al-
most doubling the estimated for 1990 which stood at 60 
million. In the South East Asia, we estimated about 66.4 
million COPD cases in 2010. Comparing our results to 
other estimates from previous studies, in the PLATINO 
multicentre study conducted across five South–American 
cities, which applied the same survey approach as the 2005 
BOLD study, crude prevalence of COPD ranged from 7.8% 
in Mexico city to 19.7% in Montevideo [23]. A total of 12.2 
million COPD cases, corresponding to an overall preva-
lence of 14.3%, was estimated for the urban population 
[23]. A mathematical model derived from prevalence of 
known COPD risk factors in 12 Asia–Pacific sites estimat-
ed about 57 million moderate–to–severe COPD cases in 
people aged 30 years or more in 2002, which is equivalent 
to a prevalence of 6.3% in the Asia Pacific region [158]. 
This figure is considerably larger than the WHO estimate 
for the region, which stood at 3.9% [157]. In addition, the 
regional working group reported that the number of COPD 
cases in China in 2002 should be expected to reach 38.2 
million, with a prevalence of 6.5% [158]. This is again 
about 2.5 times higher than the estimates reported by the 
WHO [157]. Such differences in the regional pooled prev-
alence rates reported by separate authors may be linked to 
heterogeneities arising from differences in survey method-
ologies, population structure, subject’s age and case iden-
tification [159]. Moreover, experts have reported that de-
spite the apparently large burden of COPD in Western 
Pacific and South East Asia, there are few good epidemio-
logical surveys on COPD in these regions [22]. For exam-
ple, in a recent review in India, McKay and colleagues re-
ported that they could not identify a single high quality 
study that provided detailed estimate of COPD prevalence 
using a relatively standard spirometry-based definition, and 
were therefore unable to perform a meta–analysis [160]. 
This was also observed in our study, as there were only 
Table 4. Summary of overall COPD cases and prevalence rates in people aged 30 years or more (estimates derived from epidemiologi-
cal model)
1990 2010 % inCrease in CoPd Cases
Cases (millions) Prevalence (%) Cases (millions) Prevalence (%)
World 227.3 10.7 (7.3–14.0) 384.0 11.7 (8.4–15.0) 68.9
AFRO 14.1 9.8 (8.9–10.7) 28.5 11.4 (10.5–12.3) 102.1
AMRO 41.6 13.3 (12.9–13.7) 72.0 15.2 (14.9–15.5) 73.1
EMRO 13.4 11.8 (10.1–13.5) 29.3 13.4 (11.8–15.1) 118.7
EURO 54.2 11.8 (11.6–12.0) 66.4 13.7 (13.5–13.9) 22.5
SEARO 44.5 7.9 (7.5–8.4) 75.1 9.7 (9.3–10.1) 68.8
WPRO 59.5 9.2 (9.0–9.4) 112.7 11.1 (10.9–11.3) 89.4
Urban 120.9 13.2 (10.0–16.4) 230.3 13.6 (11.2–16.9) 90.5
Rural 106.3 8.8 (6.5–11.1) 153.7 9.7 (7.6–11.8) 44.6
COPD – chronic obstructive pulmonary disease
Figure 4. Overall pooled crude prevalence of COPD by World Bank income 
category.
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three studies retained in India with only two of these pro-
viding age– and sex–specific COPD prevalence rates. How-
ever, we managed to include several large epidemiological 
surveys conducted in China, which actually had the high-
est number of retained studies (22 studies) of all the 52 
countries represented (see Table s4 in Online Supplemen-
tary Document).
In the WHO EURO region, we noted the lowest increase 
in total number of COPD cases between 1990 and 2010 
(22%). This may reflect the reduction in prevalence of 
smoking in Europe through intensive public health mea-
sures and legal regulations. According to the European 
Health Interview Survey (EHIS), the prevalence of COPD 
in 2008 among people aged at least 15 years in 16 EU 
member states ranged from 1.2% to 6.2%, with a mean 
prevalence of 3.1% [161], but EHIS was based on patient's 
self–reported diagnosis of COPD. Experts have raised con-
cerns that COPD is often under–diagnosed when based on 
self-reporting of COPD diagnosis, even in high–income set-
tings, and that the true prevalence rates may be consider-
ably higher [162].
Several authors have reported that the epidemiological ev-
idence on COPD in African region is still very limited and 
that this has affected the response to its growing burden in 
the region [16,34,163,164]. We estimated a prevalence of 
about 11% in 2010, amounting to 29 million COPD cases 
in the region. This is similar to a recent continent–wide es-
timate of more than 26 million cases in 2010 [34]. Epide-
miological data are also very limited in the Middle East and 
North Africa [165]. Based on scarce available evidence, it 
appears that the EMR had the lowest absolute number of 
COPD cases in 1990 among the world regions, with 13 
million (prevalence of 12%). However, the region then re-
corded the highest percentage increase by the year 2010 of 
119%. Smoking rates in the Middle East and in many Med-
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Figure 5. Epidemiological model based on meta–regression: The 
model is based on extracted crude COPD prevalence rates and 
adjusted for the study period and mean age of subjects from 
each study (the size of each bubble corresponds to the sample 
size from the respective study).
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iterranean countries have reportedly been high [165]. This 
may imply that the burden of COPD in EMRO region could 
have been considerably under–estimated in the year 1990.
Several studies reported that urbanization is an important 
risk in the development of COPD [9,39]. We estimated over 
230 million cases of COPD among global urban dwellers in 
2010, accounting for almost 60% of all COPD cases. The 
rapid rate of urbanization in many parts of the world, espe-
cially in LMIC, may contribute to an increasing prevalence 
of COPD globally [39]. Moreover, the prevalence of COPD 
among men was consistently higher than in women across 
all world regions, settings and income categories. Some au-
thors question the independent etiological role of gender in 
the development of COPD [166], given that the risk profile 
among men favours the development of disease. Recent re-
views suggested that increased tobacco use among women 
in high–income countries and the higher risk of exposure to 
indoor air pollution (such as biomass fuels used for cooking 
and heating) in low– and middle income countries may con-
tribute to reducing gender differences in the future [1].
Our study has a number of limitations. Although we iden-
tified a considerable number of studies for this review, they 
were not proportionately distributed across the WHO re-
gions, nor were the sample sizes from the regions propor-
tional to regional ppopulations. More than 46% of the data 
points were from the European region, meaning that the 
overall results may over–represent the burden of COPD in 
Europe. On the other hand, African region (4%), South 
East Asian region (4%) and Eastern Mediterranean region 
(5%) are all grossly under–represented, highlighting the 
lack of good quality prevalence data outside of the high–
income countries.
Another important limitation relates to the differences in 
case definitions and diagnostic guidelines employed across 
studies over time. In our analysis, we required spirometry 
as the standard diagnostic parameter, given the concerns 
raised over alternative definitions of COPD. Across all re-
tained studies, the definition based on FEV/FVC<70% was 
used in the large majority of studies, but this still doesn't 
address all possible sources of variation in case definition. 
Some authors even question the use of a fixed FEV
1
/FVC 
ratio mainly because it has no statistical basis and because 
choosing 0.7 as a cut, off point – instead of 0.68 or 0.72, 
for example – is essentially arbitrary [29]. Experts have ar-
gued that this fixed criterion may potentially over–diagnose 
COPD in the elderly, as lung elasticity decreases with age, 
which reduces FEV
1
 more than FVC [30]. Hence, using a 
fixed ratio can result in under–diagnoses in younger pa-
tients, and more frequent diagnoses in the elderly. The use 
of a lower limit of normal (LLN) has been suggested in-
stead, and this is described as the lower fifth percentile of 
a reference population [31]. It is calculated by subtracting 
the standard deviation (multiplied by 1.64) from the mean 
[31]. However, some studies suggest that LLN may miss 
subjects with COPD [32]. This variation in COPD diagno-
sis is especially pertinent in LMICs, where undiagnosed or 
poorly treated asthma, bronchiectasis, tuberculosis or some 
other obstructive airway disease may be more prevalent 
and possibly misdiagnosed as COPD [17]. Even when the 
FEV/FVC<70% criterion was consistently applied, some 
studies were based on pre–bronchodilator values, rather 
than post–bronchodilator values, as recommended by 
GOLD. In addition, it was often not fully explained how 
exactly was spirometry performed and what was the pro-
tocol. A number of technical issues could have affected the 
estimates, such as the choice of spirometer, the level of 
training of the operator, and the process of collection and 
storage of spirometry measurements. Finally, physicians’ 
knowledge of guidelines can also pose a barrier to spirom-
etry use in settings where it is available [167].
An additional limitation is associated with the choice of our 
epidemiological model, which was mainly based on age of 
the examinees. There are several other important predic-
tors that could have been incorporated into the model if 
the information was available from the retained studies, in-
cluding those related to study sites, income levels, smok-
ing, socio–economic determinants of health, occupational 
exposures and others. However, the studies that we re-
tained would rarely report these important covariates, so 
we could not use them in our model.
Meanwhile, it is worth noting that most of the studies 
(83%) included in this review were published after the year 
2000, and encouragingly, the number of epidemiological 
studies focusing on COPD has been steadily increasing over 
the past two decades. This upward trend provides an indi-
cation of an increased awareness and recognition of COPD 
as a growing global health burden, and the need to strength-
en research base and improve and standardize the methods.
Our findings suggest a high and growing prevalence of 
COPD, both globally and regionally, with substantial varia-
tion in trends between different world regions. The estimates 
presented here are consistent with other spirometry–based 
reviews on the burden of COPD. As with any other public 
health problem, increased political commitment and fund-
ing remains crucial, particularly in LMIC settings. Govern-
ments and policymakers must consider strengthening regu-
lations to address occupational and environmental risk 
factors, regulate tobacco use and improve public awareness. 
A combined use of patient- and physician targeted educa-
tional interventions could also help [168]. The efforts of 
BOLD, aiming to standardize methodology and definitions, 
must be supported, and other research entities should 
strongly consider adopting similar methods or collaborating 
with BOLD in order to provide epidemiological results that 
are more comparable in and among populations. It is only 
through such concerted effort that the current high global 
COPD burden may be reduced in the coming decades.
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